Low-dose aspirin for primary prevention of cardiovascular disease

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Atherosclerosis and plaque rupture are primary drivers of acute cardiovascular events.
• Acetylsalicylic acid (aspirin) is established for secondary cardiovascular event prevention.
• Primary prevention strategies require robust evidence for efficacy and safety.

Purpose of the Study:

• To evaluate the efficacy of aspirin as a primary preventive measure for cardiovascular events.
• To recalculate risk reductions for aspirin use in individuals without pre-existing cardiovascular disease.

Main Methods:

• Data extraction from existing randomized trials on aspirin prevention.
• Recalculation of relative and absolute risk reductions, including confidence intervals.
• Analysis focused on death, myocardial infarction, and cerebrovascular accidents.

Main Results:

• Aspirin use reduced myocardial infarction incidence in healthy men over 45, those with increased cardiovascular risk, and individuals with diabetes or hypertension.
• Aspirin demonstrated a neutral effect on cerebrovascular events in these populations.
• The protective effect of aspirin was most pronounced in individuals at higher risk for atherosclerotic vascular disease.

Conclusions:

• Aspirin shows benefit in primary prevention by reducing myocardial infarction, especially in at-risk groups.
• The decision to prescribe aspirin for primary prevention requires balancing cardiovascular benefits against bleeding risks.
• Individualized patient assessment is crucial for optimizing aspirin therapy decisions.